Citi analyst Geoff Meacham raised the firm’s price target on Regeneron (REGN) to $660 from $650 and keeps a Buy rating on the shares. The firm adjusted price targets in the biotechnology and pharmaceuticals sector as part of a Q3 earnings preview. The group is well positioned into the second half of 2025 and 2026 as policy overhangs ease and investor focus returns to fundamentals, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron announces updated data for DB-OTO due to OTOF gene
- Regeneron and Bayer Complete Long-term Study on Retinopathy of Prematurity Treatments
- Regeneron Completes Study on Aflibercept’s Safety in Real-World Settings
- Regeneron’s Odronextamab Study Update: A Potential Game-Changer in B-Cell Malignancies
- Regeneron price target lowered to $756 from $761 at Morgan Stanley